• Who we are
    • Basilea at a glance
    • Vision and mission
    • Sustainability
    • Organization
    • 25 years Basilea
  • What we do
    • Our portfolio
    • Disease areas
    • Our products and pipeline
  • Investor center
    • Investing in Basilea
    • Current presentation
    • Financial reports
    • Events and presentations
    • Annual General Meeting
    • Analyst coverage
    • Share information
    • Convertible bonds
    • Corporate Governance
    • Sustainability (ESG)
    • Stay informed
  • Careers
    • Career Openings
    • Working at Basilea
    • What we offer
  • News
  • Contact
    • Directions

News

News Subscription

Nov 04. 2025 / Ad hoc announcement
Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 30 million milestone payment to Basilea
Read more
Download
Sep 25. 2025 / Ad hoc announcement
Basilea awarded BARDA contract for the development of novel oral phase 3-ready antibiotic ceftibuten-ledaborbactam
Read more
Download
Sep 16. 2025 / Ad hoc announcement
Basilea receives USD 25 million funding under BARDA agreement to continue to advance novel antifungals fosmanogepix and BAL2062
Read more
Download
Aug 19. 2025 / Ad hoc announcement
Basilea on track with strong 2025 half-year results
Read more
Download
Aug 14. 2025 / Ad hoc announcement
Basilea announces in-licensing of a novel clinical phase 3-ready oral antibiotic
Read more
Download
Jul 29. 2025
Basilea initiates phase 3 study with antifungal fosmanogepix in invasive mold infections
Read more
Download
Jul 08. 2025 / Ad hoc announcement
Basilea receives USD 39 million funding under BARDA agreement to continue to advance novel antifungals fosmanogepix and BAL2062
Read more
Download
Jun 05. 2025
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers further milestone payment to Basilea
Read more
Download
May 20. 2025
Basilea announces commercial availability of antibiotic Zevtera® (ceftobiprole) in the United States
Read more
Download
Apr 24. 2025
Strong sales for Cresemba® (isavuconazole) in Japan trigger second milestone payment from Asahi Kasei Pharma to Basilea
Read more
Download
  • previous
  • 1
  • 2
  • 3
  • …
  • 32
  • next
  • Who we are
    • Basilea at a glance
    • Vision and mission
    • Sustainability
    • Organization
    • 25 years Basilea
  • What we do
    • Our portfolio
    • Disease areas
    • Our products and pipeline
  • Investor center
    • Investing in Basilea
    • Current presentation
    • Financial reports
    • Events and presentations
    • Annual General Meeting
    • Analyst coverage
    • Share information
    • Convertible bonds
    • Corporate Governance
    • Sustainability (ESG)
    • Stay informed
  • Careers
    • Career Openings
    • Working at Basilea
    • What we offer

Basilea Pharmaceutica International Ltd, Allschwil
Hegenheimermattweg 167b
4123 Allschwil
Switzerland

P: +41 61 606 11 11
E-mail: info@basilea.com

News subscription
  • Imprint
  • Terms of use and Privacy Notice
  • EFPIA Disclosure Code
  • Expanded Access Policy
  • Transparence des liens d’intérêt

© 2026 Basilea Pharmaceutica Ltd, Allschwil